BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27523002)

  • 1. Radiological and Pathological Correlation in Anti-MDA5 Antibody-positive Interstitial Lung Disease: Rapidly Progressive Perilobular Opacities and Diffuse Alveolar Damage.
    Chino H; Sekine A; Baba T; Iwasawa T; Okudela K; Takemura T; Itoh H; Sato S; Suzuki Y; Ogura T
    Intern Med; 2016; 55(16):2241-6. PubMed ID: 27523002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interstitial Lung Disease with Anti-melanoma Differentiation-associated Protein 5 Antibody: Rapidly Progressive Perilobular Opacity.
    Chino H; Sekine A; Baba T; Kitamura H; Iwasawa T; Okudela K; Takemura T; Itoh H; Sato S; Suzuki Y; Ogura T
    Intern Med; 2019 Sep; 58(18):2605-2613. PubMed ID: 31178482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis.
    Suzuki A; Kondoh Y; Taniguchi H; Tabata K; Kimura T; Kataoka K; Ono K; Hashisako M; Fukuoka J
    Respir Med Case Rep; 2016; 19():5-8. PubMed ID: 27354955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cytokine profiles of patients with interstitial lung disease associated with anti-CADM-140/MDA5 antibody positive amyopathic dermatomyositis.
    Takada T; Aoki A; Asakawa K; Sakagami T; Moriyama H; Narita I; Sato S
    Respir Med; 2015 Sep; 109(9):1174-80. PubMed ID: 26187000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi N; Takezaki S; Kobayashi I; Iwata N; Mori M; Nagai K; Nakano N; Miyoshi M; Kinjo N; Murata T; Masunaga K; Umebayashi H; Imagawa T; Agematsu K; Sato S; Kuwana M; Yamada M; Takei S; Yokota S; Koike K; Ariga T
    Rheumatology (Oxford); 2015 May; 54(5):784-91. PubMed ID: 25288783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rheumatoid Arthritis Complicated with Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Interstitial Pneumonia.
    Matsumoto H; Sato S; Fujita Y; Yashiro-Furuya M; Matsuoka N; Asano T; Kobayashi H; Watanabe H; Migita K
    Intern Med; 2019 Mar; 58(5):737-742. PubMed ID: 30333415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
    Chen F; Li S; Wang T; Shi J; Wang G
    Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy.
    Sasano H; Hagiwara E; Kitamura H; Enomoto Y; Matsuo N; Baba T; Iso S; Okudela K; Iwasawa T; Sato S; Suzuki Y; Takemura T; Ogura T
    BMC Pulm Med; 2016 Dec; 16(1):168. PubMed ID: 27903248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Perilobular pulmonary opacities: high-resolution CT findings and pathologic correlation.
    Johkoh T; Müller NL; Ichikado K; Nakamura H; Itoh H; Nagareda T
    J Thorac Imaging; 1999 Jul; 14(3):172-7. PubMed ID: 10404502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimelanoma differentiation-associated protein 5 antibody level is a novel tool for monitoring disease activity in rapidly progressive interstitial lung disease with dermatomyositis.
    Matsushita T; Mizumaki K; Kano M; Yagi N; Tennichi M; Takeuchi A; Okamoto Y; Hamaguchi Y; Murakami A; Hasegawa M; Kuwana M; Fujimoto M; Takehara K
    Br J Dermatol; 2017 Feb; 176(2):395-402. PubMed ID: 27452897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies.
    Shi J; Li S; Yang H; Zhang Y; Peng Q; Lu X; Wang G
    J Rheumatol; 2017 Jul; 44(7):1051-1057. PubMed ID: 28461650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
    Sato S; Kuwana M; Fujita T; Suzuki Y
    Mod Rheumatol; 2013 May; 23(3):496-502. PubMed ID: 22644102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Oga T; Chin K; Nagai S; Mimori T; Mishima M
    Respir Med; 2011 Sep; 105(9):1380-7. PubMed ID: 21632230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical analysis and outcome of interstitial lung disease complicated with juvenile dermatomyositis and juvenile polymyositis.
    Sato S; Uejima Y; Nanbu M; Suganuma E; Takano T; Tanaka R; Kabuki T; Oguma E; Oh-Ishi T; Kawano Y
    Mod Rheumatol; 2017 Jul; 27(4):652-656. PubMed ID: 27588444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis.
    Gono T; Sato S; Kawaguchi Y; Kuwana M; Hanaoka M; Katsumata Y; Takagi K; Baba S; Okamoto Y; Ota Y; Yamanaka H
    Rheumatology (Oxford); 2012 Sep; 51(9):1563-70. PubMed ID: 22589330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.
    Xu Y; Yang CS; Li YJ; Liu XD; Wang JN; Zhao Q; Xiao WG; Yang PT
    Clin Rheumatol; 2016 Jan; 35(1):113-6. PubMed ID: 26660480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies.
    Sato S; Murakami A; Kuwajima A; Takehara K; Mimori T; Kawakami A; Mishima M; Suda T; Seishima M; Fujimoto M; Kuwana M
    PLoS One; 2016; 11(4):e0154285. PubMed ID: 27115353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.